<?xml version='1.0' encoding='utf-8'?>
<document id="21123164"><sentence text="Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor."><entity charOffset="77-87" id="DDI-PubMed.21123164.s1.e0" text="boceprevir" /></sentence><sentence text="Boceprevir (SCH 503034), a protease inhibitor, is under clinical development for the treatment of human hepatitis C virus infections"><entity charOffset="0-10" id="DDI-PubMed.21123164.s2.e0" text="Boceprevir" /></sentence><sentence text=" In human liver microsomes, formation of oxidative metabolites after incubations with [(14)C]boceprevir was catalyzed by CYP3A4 and CYP3A5"><entity charOffset="86-103" id="DDI-PubMed.21123164.s3.e0" text="[(14)C]boceprevir" /></sentence><sentence text=" In addition, the highest turnover was observed in recombinant CYP3A4 and CYP3A5" /><sentence text=" After a single radiolabeled dose to human, boceprevir was subjected to two distinct pathways, namely cytochrome P450-mediated oxidation and ketone reduction"><entity charOffset="44-54" id="DDI-PubMed.21123164.s5.e0" text="boceprevir" /><entity charOffset="141-147" id="DDI-PubMed.21123164.s5.e1" text="ketone" /><pair ddi="false" e1="DDI-PubMed.21123164.s5.e0" e2="DDI-PubMed.21123164.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21123164.s5.e0" e2="DDI-PubMed.21123164.s5.e1" /></sentence><sentence text=" Therefore, attempts were made to identify the enzymes responsible for the formation of carbonyl-reduced metabolites"><entity charOffset="88-96" id="DDI-PubMed.21123164.s6.e0" text="carbonyl" /></sentence><sentence text=" Human liver S9 and cytosol converted ∼ 28 and ∼ 68% of boceprevir to M28, respectively, in the presence of an NADPH-generating system"><entity charOffset="56-66" id="DDI-PubMed.21123164.s7.e0" text="boceprevir" /></sentence><sentence text=" Screening of boceprevir with recombinant human aldo-keto reductases (AKRs) revealed that AKR1C2 and AKR1C3 exhibited catalytic activity with respect to the formation of M+2 metabolites (M28 and M31)"><entity charOffset="14-24" id="DDI-PubMed.21123164.s8.e0" text="boceprevir" /></sentence><sentence text=" The formation of M28 was inhibited by 100 μM flufenamic acid (80"><entity charOffset="46-61" id="DDI-PubMed.21123164.s9.e0" text="flufenamic acid" /></sentence><sentence text="3%), 200 μM mefenamic acid (83"><entity charOffset="12-26" id="DDI-PubMed.21123164.s10.e0" text="mefenamic acid" /></sentence><sentence text="7%), and 100 μM phenolphthalein (86"><entity charOffset="16-31" id="DDI-PubMed.21123164.s11.e0" text="phenolphthalein" /></sentence><sentence text="1%), known inhibitors of AKRs, suggesting its formation through carbonyl reduction pathway"><entity charOffset="64-72" id="DDI-PubMed.21123164.s12.e0" text="carbonyl" /></sentence><sentence text=" Formation of M28 was also inhibited by 100 μM diazepam (75"><entity charOffset="47-55" id="DDI-PubMed.21123164.s13.e0" text="diazepam" /></sentence><sentence text="1%), 1 mM ibuprofen (70%), and 200 μM diflunisal (89"><entity charOffset="10-19" id="DDI-PubMed.21123164.s14.e0" text="ibuprofen" /></sentence><sentence text="4%)" /><sentence text=" These data demonstrated that CYP3A4 and CYP3A5 are primarily responsible for the formation of oxidative metabolites and the formation of M28 and M31, the keto-reduced metabolites, are most likely mediated by AKR1C2 and AKR1C3" /><sentence text=" Because the biotransformation and clearance of boceprevir involves two different enzymatic pathways, boceprevir is less likely to be a victim of significant drug-drug interaction with concomitant medication affecting either of these pathways"><entity charOffset="48-58" id="DDI-PubMed.21123164.s17.e0" text="boceprevir" /><entity charOffset="102-112" id="DDI-PubMed.21123164.s17.e1" text="boceprevir" /><pair ddi="false" e1="DDI-PubMed.21123164.s17.e0" e2="DDI-PubMed.21123164.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21123164.s17.e0" e2="DDI-PubMed.21123164.s17.e1" /></sentence><sentence text="" /></document>